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Electron microscopyPRIMA-1 is a chemical compound identiﬁed as a growth suppressor of tumor cells expressing mutant p53.
We previously found that in the MDA-MB-231 cell line expressing high level of the mutant p53-R280K
protein, PRIMA-1 induced p53 ubiquitination and degradation associated to cell death. In this study, we
investigated the ability of PRIMA-1 to induce autophagy in cancer cells. In MDA-MB-231 and HCT116 cells,
expressing mutant or wild type p53, respectively, autophagy occurred following exposure to PRIMA-1, as
shown by acridine orange staining, anti-LC3 immunoﬂuorescence and immunoblots, as well as by electron
microscopy. Autophagy was triggered also in the derivative cell lines knocked-down for p53, although to a
different extent than in the parental cells expressing mutant or wild type p53. In particular, while wild
type p53 limited PRIMA-1 induced autophagy, mutant p53 conversely promoted autophagy, thus sustaining
cell viability following PRIMA-1 treatment. Therefore, the autophagic potential of PRIMA-1, besides being cell
context dependent, could be modulated in a different way by the presence of wild type or mutant p53. Fur-
thermore, since both cell lines lacking p53 were more sensitive to the cytotoxic effect of PRIMA-1 than the
parental ones, our ﬁndings suggest that a deregulated autophagy may favor cell death induced by this drug.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
In the last ten years a big effort has been employed in the identi-
ﬁcation and characterization of small molecules that target mutant
p53 expressed in tumor cells [1]. One of these molecules, PRIMA-1 (for
p53-reactivation and induction of massive apoptosis) has been identiﬁed
as a compound that selectively inhibits the growth of tumor cells express-
ing mutant p53, by restoring the sequence-speciﬁc DNA-binding and
transactivation functions of at least some mutant p53 proteins and pro-
moting apoptosis [2]. It has been reported that into the cell, PRIMA-1
and its methylated form PRIMA-1Met are converted to active products
that form alkylated thiol groups in cysteine-containing proteins, includ-
ing mutant p53; such a protein modiﬁcation is considered sufﬁcient to
restore the tumor suppressor activity of p53 and induce apoptosis [3].
To date, a number of evidences support the notion that following
p53 reactivation by PRIMA-1, different transcription-dependent and
-independent pathways converging on apoptosis are indeed activated
[4–6]. Interestingly, in human osteosarcoma Saos-2 cells PRIMA-1 hasd DNA Repair Unit, IRCCS AOU
9 010 555 8225; fax: +39 010
ini).
l rights reserved.also been shown to induce several genes associated with the accu-
mulation of unfolded proteins and endoplasmic reticulum (ER)
stress such as XBP1, GRP78 and DNAJB2 [6–8]. Furthermore, a signif-
icant increase of the level of HSP70, a chaperone involved in protein
folding, has been documented following PRIMA-1 treatment in different
cell lines expressing mutant p53 [9,10]. In mutant p53 carrying cells,
PRIMA-1 can also induce production of reactive oxygen species (ROS)
[3], which in turn could trigger ER stress [11,12]. Conditions that disrupt
ER function, including oxidative stress or accumulation of unfolded/
misfolded proteins, may result in the unfolded protein response (UPR),
a survival response acting to resolve deregulation of protein-folding path-
ways [13,14]. However, if the normal environment cannot be restored,
the response to ER stress is switched from survival to apoptosis. Interest-
ingly, accumulating evidence suggests that the ERmay play an important
role not only in apoptosis but also in the regulation of autophagy [15].
Autophagy is a dynamic catabolic process in which cellular proteins,
organelles, and cytoplasmic constituents are degraded and recycled to
sustain cell metabolism [16,17]. At the ﬁrst step of autophagy, a double
membrane engulfs cytoplasmic components and forms vesicles called
“autophagosomes”. Afterwards, the fusion of autophagosomes with
lysosomes results in the formation of autophagolysosomes, where the
sequestered contents are degraded and recycled for protein and ATP
synthesis [18,19]. The role of autophagy in modulating tumor growth
is undoubtedly complex. At the stage of tumor development, autophagy
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the observation that deletions of autophagic genes such as UVRAG
and beclin1 are frequently found in human cancers [20–22]. On the
other side, the activation of autophagy often occurring in the poorly
vascularized central areas of a solid tumor may function as a survival
mechanism against hypoxia and nutrient deprivation. In this case, au-
tophagy may contribute to tumor progression by enhancing oncogenic
functions [22,23].
It is known that the regulation of autophagy depends on an intri-
cate network of proteins among which p53, a key component of the
cellular response to different types of stress [24], may play a dual role
[25]. In fact, whereas wild type p53 may inhibit autophagy when local-
ized in the cytoplasm [26], after its transfer into the nucleus it can
transactivate pro-autophagic genes such as DRAM [27]. However, it
has been shown that deletion of wild type p53 can favor autophagy
induction in human and mouse cells, indicating that p53 may act as
an endogenous repressor of the autophagic process [26].
We have previously found that in the MDA-MB-231 cell line deriving
from a human breast carcinoma and expressing high level of the mutant
p53-R280K protein, PRIMA-1 induced a signiﬁcant nucleolar redistribu-
tion of mutant p53, associated to p53 degradation via ubiquitination,
and cell death. Our results suggested that in some cellular context,
PRIMA-1 cytotoxicity could be at least partially due to the triggering of
a protein degradation pathway that removes a pro-survival function of
the mutant p53 itself [10].
On the basis of these evidences, and to get insights into the involve-
ment of p53 in the autophagic process, in this study we investigate the
ability of PRIMA-1 to induce autophagy in cancer cells carrying mutant
or wild type p53 protein, such as MDA-MB-231 and HCT116 cells, re-
spectively, and in their derivative cell lines knocked-down for p53.
2. Materials and methods
2.1. Cell culture and drug treatment
MDA-MB-231 cell line (human breast carcinoma) carrying the
p53-R280Kmutation [28], as conﬁrmed by us (not shown),was authen-
ticated by DNA (STR) proﬁling (DSMZ, Braunschweig, Germany). The
mutant p53 knocked-down T1 cell line was obtained as described
[10]. HCT116 wt p53+/+and HCT116 wt p53−/− cells were obtained
byDr. B. Vogelstein (The JohnsHopkinsKimmel Cancer Center, Baltimore,
MD). MCF7 (wild type p53), DLD1 (mutant p53-S241F) and normal
MRC5 (wild type p53) cellswere obtained by the Interlab Cell Line Collec-
tion (ICLC Genova, Italy). Cells were grown in D-MEM (MDA-MB-231, T1,
MCF7), RPMI (HCT116, DLD1) andMEM(GIBCO Invitrogen,Milano, Italy)
containing 5% (MDA-MB-231, T1) and 10% (DLD1, HCT116, MRC5) foetal
bovine serum (Euroclone, Milano, Italy), and maintained at 37 °C in
5% CO2 at 100% humidity. PRIMA-1 (Calbiochem-Merck, Milan, Italy)
was dissolved in H2O at a concentration of 10 mM and working solu-
tions were then prepared by appropriate dilutions in PBS. Rapamycin
(Sigma-Aldrich, Milano, Italy) was dissolved in DMSO at a concentra-
tion of 2.74 mM. Starvation medium was obtained by adding 0.25 %
serum to D-MEM and 0.5% serum to RPMI for MDA-MB-231/T1 and
HCT116 cells, respectively.
2.2. Detection of acidic vesicular organelles (AVOs)
At 24 h after treatment, cells were incubated with medium
containing 1 μg/ml acridine orange (Sigma-Aldrich, Milano, Italy) for
15 min at room temperature. The acridine orange was then removed,
and unﬁxed cellswere rapidlywashed in freshmediumand immediate-
ly examined by ﬂuorescence microscopy. Micrographs were taken
using an epiﬂuorescence Provis AX70 microscope (Olympus, Tokyo,
Japan) and Cytovision software (Applied Imaging Corp., Santa Clara,
CA, USA). Autophagy occurrence was based on the presence of cellsdisplaying intense red staining in response to a given experimental
treatment.
2.3. Immunocytochemistry and LC3 detection
Cells were seeded on coverslips and treated for 24 h. At the
end of treatments, slides were washed twice with PBS, ﬁxed in
1:1 methanol:acetone and incubated with anti MAPLC3 antibody
(Sigma-Aldrich, Milano, Italy) for 1 h at 37 °C, followed by an anti-
rabbit FITC-conjugated antibody (Sigma-Aldrich, Milano, Italy). Slides
were then counterstained by 4,6-diamidino-2-phenylindole (DAPI).
Amount of cells containing LC3-puncta was determined by scoring at
least 100 cells and documented as described above.
2.4. Western blot analysis
Standard cell extracts were prepared as described [29]. Anti
MAPLC3 (L8918, Sigma-Aldrich, Milano, Italy) and anti β-actin
(AC-74, Sigma-Aldrich, Milano, Italy) antibodies were employed.
Secondary anti-mouse IgG peroxidase conjugate (A9044) and secondary
anti-rabbit peroxidase conjugate (A9169) were from Sigma-Aldrich.
Detection was carried out with ECL-Plus Western Blotting Detection
System (Amersham, Milano, Italy).
2.5. Electron microscopy analysis
Cultured cells were ﬁxed in 2.5% glutaraldehyde in 0.1 M phos-
phate buffer (pH 7.3) for 20 min at room temperature, washed in
0.1 M phosphate buffer (pH 7.4), post-ﬁxed in 0.1% osmium tetrox-
ide in 0.1 phosphate buffer (pH 7.4) and dehydrated in a graded
series of ethanol. During the last de-hydration phase, the cells were
scraped and centrifuged to obtain a pellet that was brieﬂy transferred
to propylene oxide and embedded in PolyBed 812 (Polyscience Inc.,
Warrington, Pa, USA). Ultrathin sections were cut with a diamond knife,
stained with uranyl acetate and lead citrate and observed under a
Zeiss 902 transmission electron microscope [30]. Autophagic vacu-
oles (AV) were identiﬁed as double-membraned vesicles containing
degenerating cytoplasmatic organelles or cytosol, while residual bodies
(RB) were identiﬁed as single-membraned electron dense bodies con-
taining unidentiﬁable material [16,31]. Morphometric analyses were
performed by stereological techniques [32]. In particular, the volume
density of AV and RB was estimated. Ten microphotographs of each ex-
perimental condition were taken, at an original magniﬁcation of ×3000.
Volume density values derived from the evaluation of 15–20 different
cells for each cell category (in most micrographs there were more
than one cell). The cytoplasm was used as reference area. A graticule
(11 × 11) composed of 169 points was placed on the micrographs
and the number of points intersecting the AVs was counted. Volume
density of AV was calculated according to the formula: volume densi-
ty = Pi/Pt, where Pi is the number of points within the subcellular
component and Pt is the total number of points, and expressed in
ml/100 ml of tissue (ml%) [32]. The number of AV and RB per area
unit was calculated as the mean of the number of these subcellular
components contained in a photographic area corresponding to a
real area of 220 μm2 [33].
2.6. Real-time monitoring of cell proliferation
The xCELLigence Real-Time Cell Analyzer (RTCA) Instrument®
(Roche) monitors cell proliferation in real time by measuring electrical
impedance across micro-electrodes integrated on the bottom of special
tissue culture plates (E-plates). Cell spreading and proliferation are
expressed as an arbitrary unit called Cell Index (CI), which is the result
of the number of cells, cell morphology and cellular adhesion to the
plates [34]. For cell proliferation assays, 50 μl of media was added to
the E-plate to obtain background readings, followed by the addition of
1906 D. Russo et al. / Biochimica et Biophysica Acta 1833 (2013) 1904–191350 μl of cell suspension at different densities depending on cell
type. The E-plates containing the cells were incubated at room tem-
perature for 30 min and placed on the reader in the incubator.
Impedance-based CI was measured with time intervals varying
from 5 to 30 min. After 24 h the cells were treated with different
concentrations of PRIMA-1 and monitored every 30 min for the
designed period of time.
3. Results
3.1. PRIMA-1 induces autophagy in cancer cells carrying mutant p53
To determine whether PRIMA-1 can induce autophagy we used dif-
ferent approaches. First, we used an assay that measures supravital
staining of acidic compartments. Indeed, in the late phase of autophagy,
the autophagolysosome generates an acidic compartment which can
be stained with acridine orange (bright red or orange ﬂuorescence)
[35,36]. An increase in acridine orange-positive acidic vesicular
organelles (AVOs) occurs in conjunction with the induction of au-
tophagy [37,38]. In MDA-MB-231 cells the presence of red AVOs fol-
lowing PRIMA-1 treatment (200 μΜ), as well as serum-deprivation or
rapamycin, twowell-known stimuli used as positive controls of autoph-
agy induction, was detected (Fig. 1A). In contrast, mock-treated cells
exhibited minimal red ﬂuorescence. Interestingly, the inductionStarvedMock
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Fig. 1. Induction of autophagy in MDA-MB-231 and DLD1 cells. A) MDA-MB-231 cells we
Supravital cell staining with acridine orange was performed after 24 h of treatment.
serum-starved, rapamycin and PRIMA-1 treated cells, bright red acidic vescicular organell
and LC3-II bands detected with the anti-LC3 antibody in serum-starved, rapamycin and PR
of the images from 3 to 5 independent experiments; the amount of LC3-II form was normaliz
ing with an antibody against endogenous LC3. Representative images from two independen
in the histogram. E) DLD1 cells were mock-treated or treated for 24 h with 50 μM PRIMA-1
tative western blots showing LC3-I and LC3-II bands in PRIMA-1-treated DLD1 cell lysates.
three independent experiments; the amount of LC3-II form was normalized for β-actin an
form in 100 μM PRIMA-1 compared to mock-treated cells was statistically signiﬁcant (*p =of AVOs by PRIMA-1 appears at least as strong as that determined
by rapamycin and stronger than after starvation, suggesting that
PRIMA-1 is quite efﬁcient in triggering the autophagic response.
The microtubule-associated protein 1 light chain 3 (LC3) was
used as further marker of autophagy. When autophagy is not acti-
vated, LC3 is localized homogeneously in the cytoplasm, while
upon initiation of autophagy, it associates with the membrane
of autophagosomes. An antibody against endogenous LC3 protein was
used to detect autophagy by immunoﬂuorescence. As shown in Fig. 1C,
in MDA-MB-231 cells, a variable number of large LC3 puncta of intense
green cytoplasmic ﬂuorescence, likely representing LC3 bound to AVs,
appeared after exposure of cells to starvation, rapamycin and PRIMA-1.
While mock cells were negative for green LC3 puncta, a small number
of positive cells were observed after serum starvation, whereas a marked
increase of cells containing LC3 puncta was detected after 200 μM
PRIMA-1 treatment (Fig 1C, D). The presence andmodulation of activat-
ed 16-kDa LC3-II isoform, derived from the autophagy-related proteo-
lytic conversion of the 18-kDa precursor LC3-I [39], was also checked
by western blot (Fig 1B). The level of LC3-II was already high in
untreated cells and did not increase after PRIMA-1 treatment. Indeed,
high level of endogenous LC3-II under nutrient-rich conditions has
been already observed in MDA-MB-231 cells [31,40] indicating that, in
this cell line, the level of LC3-II determined by western blot may not
be a suitable marker for autophagic activity.Starved
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colon cancer cell line carrying the mutant p53S241F. In these cells,
both the appearance of LC3 positive vacuoles in immunoﬂuorescence
experiments (Fig. 1E) and the increase of LC3-II band in western blot
(Fig. 1F) were detected after exposure to PRIMA-1. This indicates
that the induction of autophagy by PRIMA-1, detected in DLD1 at
lower drug concentrations than in MDA-MB-231 cells, was not cell-type
speciﬁc. Even though the 200 μM PRIMA-1 concentration used in MDA-
MB-231 cells might appear high, in a ﬁrst-in-human study with
PRIMA-1Met (APR-246) the maximum tolerated dose, 60 mg/kg,
correlates to a maximum plasma concentration of about 300 μM [41].
Thus, the concentrations used in our in vitro experiments are compati-
ble with the doses used in those patients.
Electron microscope (EM) analysis was performed in MDA-MB-
231 cells. In the cytoplasm, mitochondria appeared often swelled
with disrupted cristae and dispersed matrix. Furthermore, markedly
dilated and fragmented ER cisternae (a clear index of ER stress) were
observed (Fig. 2A). The morphometric analysis of EM images con-
ﬁrmed that the volume density of ER in PRIMA-1 treated and starved
MDA-MB-231 cells signiﬁcantly (p b 0.05, at least) increased as com-
pared to mock cells [ER volume density (ml%): mock 0.2 ± 0.03,
PRIMA-100 μM 2.1 ± 0.15, starvation 0.6 ± 0.08]. Several double-
membraned autophagosomes or AVs were detected after starvation,
rapamycin and or PRIMA-1 treatment (Fig. 2A). At 200 μM PRIMA-1,
AVs were large and numerous, sometimes ﬁlling wide cytoplasmic
areas. In general, AVs contained membrane residues or fragmentedmi-
tochondria, these latter being more often present upon PRIMA-1 treat-
ment. Interestingly, besides classical AVs, numerous electron dense
single membrane-limited autophagolysosomes or residual bodies (RB)
were identiﬁed (Fig. 2A, lower right panel). These RBs, containing
unrecognizable material or cell debris, are believed to be the remnants
of the auto-degradative activity occurring after fusion of lysosomes
with AVs, thus representing the late steps of the autophagic process
[31]. The morphometric analysis revealed a signiﬁcant increase with re-
spect to control cells (p b 0.05) of the number and volume density of
AVs after PRIMA-1 treatment in a dose-dependent fashion, as well as
after serum starvation (Fig. 2B). On the other hand, the number andMock Starved R
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Fig. 2. Autophagy detection by EM inMDA-MB-231 cells. A) Representative EM images ofMDA-
rapamycin, starvation, 100 μMPRIMA-1 (100P) and 200 μMPRIMA-1 (200P). AVs, sometimes
reticulum. Up to 200 cells were scored. B) Histograms show the morphometric analysis of the
vation and PRIMA-1 (100 μM and 200 μM). Bars indicate standard error; *p b 0.05, at least, vsvolume density of RBs signiﬁcantly increases following 200 μM
PRIMA-1 treatment but not following starvation (Fig. 2B).
Altogether, these results indicate that PRIMA-1 is able to induce an
autophagic process in cancer cells carrying mutant p53.
3.2. PRIMA-1 induces autophagy in MDA-MB-231 cancer cells knocked-
down for mutant p53
Since p53 may have a regulatory role in autophagy [26,27], we in-
vestigated whether the presence of mutant p53 affects the autophagic
potential of PRIMA-1. To this aim, the LC3 localization was determined
in T1, a MDA-MB-231 derivative cell line in which the mutant p53 has
been knocked down by RNA interference [10]. In the absence of treat-
ment, approximately 20% of T1 cells could be classiﬁed as carrying LC3
puncta by immunoﬂuorescence analysis. A three-fold increase of LC3
puncta containing cells was observed only upon 200 μMPRIMA-1 treat-
ment (Fig 3A).
As in MDA-MB-231, in T1 cells the EM analysis revealed the pres-
ence of swelled and disrupted mitochondria with dispersed matrix.
The occurrence of ER stress was also documented; indeed, the volume
density of ER in PRIMA-treated and starved T1 cells signiﬁcantly
(p b 0.05, at least) increased as compared to mock cells [ER volume
density (ml%): mock 0.3 ± 0.05, PRIMA-100 μM 1.9 ± 0.16, starvation
2.6 ± 0.16]. A signiﬁcant increase in AV number and volume density in
both starved and 200 μM PRIMA-1 treated cells was detected (Fig. 3B,
C). On the other hand, the RB number and volume density increased fol-
lowing 100 μM PRIMA-1 while after serum starvation was signiﬁcantly
lower than in untreated cells (Fig 3C).
When a comparison between the morphometric data of MDA-
MB-231 and T1 cells was considered, we found that following treat-
ment with 200 μM PRIMA-1 the number of AVs, as well as their vol-
ume density, was signiﬁcantly lower in T1 than in MDA-MB-231
(AV n: 4.2 ± 0.2 vs 7.5 ± 0.2, p b 0.05; AV vol density: 2.7 ± 0.21
vs 3.9 ± 0.1, p b 0.05). Following starvation, there was no difference
in the number of AVs between T1 and MDA-MB-231 (AV n: 2.8 ± 0.1
vs 3.2 ± 0.5), although their volume seems to increase more in
MDA-MB-231 than in T1 cells. When the level of basal autophagyapamycin
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Fig. 3. Induction of autophagy in T1 cells. A) T1 cells were serum-starved or treated with 100 μM or 200 μM PRIMA-1 for 24 h and ﬁxed for immunostaining with an anti-LC3 an-
tibody. Representative images of endogenous LC3 from two independent experiments are shown. Bar 10 μm. In the lower panel, the percentage of LC3 puncta-containing cells is
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Fig. 4. Real-time monitoring of cell proliferation following PRIMA-1 treatment. HCT116
p53+/+and HCT116 p53−/− cells were plated in suitable E-plates and their cell
index was monitored continuously. Due to their different morphologies (with
HCT116 p53−/− cells larger than HCT116 p53+/+ cells), the untreated HCT116
p53−/− cells reached a plateau at a higher cell index than the HCT116 p53+/+
cells after approximately the same time interval. Twenty-four hours after plating, dif-
ferent concentrations of PRIMA-1 (P) were added and cell growth was monitored
every 30 min up to 144 h. The growth of HCT116 p53+/+ cells was not affected
until 36 h after the addition of 100 μM PRIMA-1. On the other hand, the HCT116
p53−/− cells stop to proliferate and level off when exposed to 50 μM PRIMA-1
while they detach from the plate approximately 12 h after the addition of 100 μM
PRIMA-1. The 200 μM PRIMA-1 concentration was very toxic for both cell lines.
1908 D. Russo et al. / Biochimica et Biophysica Acta 1833 (2013) 1904–1913was taken into consideration, also immunoﬂuorescence analysis
evidenced a lower induction of autophagy in T1 than in MDA-MB-231
cells (compare Figs. 1C,D and 3A). These observations suggest that the
presence of mutant p53 may potentiate the autophagic response to
200 μM PRIMA-1.
Thus, PRIMA-1 induced autophagy also in T1 cells lacking mutant
p53. However, the removal of mutant p53 resulted in increased levels
of basal autophagy but in reduced PRIMA-1-induced autophagy.
3.3. PRIMA-1 induces autophagy in wild type p53 carrying cancer cells
We then investigated the ability of PRIMA-1 to induce autophagy
in HCT116 cancer cells carrying or lacking wild type p53. The real
time monitoring of cell proliferation (Fig 4) (see Materials and
methods for description) showed a higher sensitivity of the HCT116
p53−/− cells to the cytotoxic effect of PRIMA-1 than their p53+/+
counterpart.
Treatment with PRIMA-1 determined a clear-cut increase in dis-
tinct LC3 puncta in both cell lines (Fig. 5A). In HCT116 p53+/+, at
50 and 100 μM PRIMA-1, an increasing number of cells showed
large ﬂuorescent agglomerates not present in untreated control
cells (Fig. 5A). Conversely, a relevant percentage of control HCT116
p53−/− cells (45%) showed tiny spots and upon treatment with
50 μM PRIMA-1, the number and brightness of these spots were en-
hanced and the percentage of cells containing them increased up to
75%. The toxicity of the 100 μM PRIMA-1 dose in these cells did not
allow the evaluation by such technique. Western blot analysis was
performed with anti-LC3 antibody (Fig. 5B). A signiﬁcant increase
in activated 16-kDa LC3-II isoform was found in both cell lines exposed
to 100 μM PRIMA-1 as compared to mock-treated cells (p b 0.005 in
100 μM PRIMA-1 vs mock in HCT116 p53+/+; p = 0.007 in 100 μM
PRIMA-1 vsmock in HCT116 p53−/−). Furthermore, a higher level of
LC3-II in both mock and 100 μM PRIMA-1 treated HCT116 p53−/−
cells compared to HCT116 p53+/+ cells was found (p b 0.05).
The EM analysis revealed the induction of numerous AVs in both
HCT116 cell lines upon PRIMA-1 treatment as well as followingstarvation (Fig. 6). In HCT116 p53−/− treated cells, AVs were larger
and more abundant than in p53+/+ treated cells. At both PRIMA-1
doses in p53−/− cells and at the higher dose in p53+/+ cells, AVs
containing still recognizable mitochondria could be observed at higher
magniﬁcation in many cells (not shown). The number and volume
density of AVs signiﬁcantly increased in both cell lines after PRIMA-1
treatment and serum starvation. Noteworthy, HCT116 p53−/− cells
presented the highest AV number when exposed to 50 μM PRIMA-1
(Fig. 6B). Also in HCT116 cells, as previously observed in MDA-MB-231
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The comparison between the morphometric data obtained in
HCT116 p53+/+ and HCT116 p53−/− cells revealed a more efﬁcientA
Fig. 6. EM analysis of HCT116 p53+/+ and HCT116 p53−/− cells after PRIMA-1 treatment a
mock cells and in numerous PRIMA-1 treated cells. An engulfment of AVs and RBs could be
PRIMA-1. B) Histograms show the morphometric analysis of the number and the volume
*p b 0.05 at least vs mock-treated cells.induction of autophagy in HCT116 p53−/− than in p53+/+ cells fol-
lowing 50 μM PRIMA-1 (AV n: 6.6 ± 0.6 vs 1.8 ± 0.3. p b 0.05; AV
vol: 2.6 ± 0.2 vs 0.7 ± 0.1, p b 0.05). Furthermore, as determined by
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observed in HCT116 p53+/+ and HCT116 p53−/− cells after incubation with 100 μM
density of AVs and RBs in HCT116 cells exposed to serum starvation and PRIMA-1.
05
10
15
20
25
mock 100P 200P
FO
LD
 in
cr
ea
se
MDA n T1 n
MDA vol T1 vol
0
10
20
30
40
mock 50P 100P
FO
LD
 in
cr
ea
se
HCT +/+ n HCT-/- n
HCT+/+ vol HCT-/- vol
mut p53 wt p53
Fig. 7. Comparison of autophagy induction following PRIMA-1 in MDA-MB-231 (mut
p53), HCT116 cells (wt p53) and their derivative p53 lacking cells. The fold increase
of AV number (n) and volume density (vol) in treated vs untreated cells was calculated
and reported for each cell line.
1910 D. Russo et al. / Biochimica et Biophysica Acta 1833 (2013) 1904–1913was higher in the untreated HCT116 p53−/− than in untreated
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In addition to HCT116 cells, autophagy was also investigated in the
MCF7 breast cancer cells and in normal, not tumor-derived MRC5 cells
carrying wild type p53. In MCF7, the appearance of LC3 positive cells
in immunoﬂuorescence assays, as well as the increase of the LC3-II
band in western blot showed an autophagic response triggered by
PRIMA-1 (see Supplementary Fig. 2). In MRC5, we could observe an in-
crease of LC3-II band following 75 μM PRIMA-1 (Supplementary Fig. 2)
suggesting the occurrence of autophagy also in normal cells.
Thus, PRIMA-1 induces autophagy in cancer cells carrying wild type
p53. However, in cells lacking wild type p53, as HCT116 p53−/− cells,
both a higher basal level of autophagy and a stronger induction of
autophagic markers following PRIMA-1 could be observed.
4. Discussion
The results of this study provide clear evidence that PRIMA-1, a
low-molecular-weight synthetic compound known to exert selective
growth inhibition of tumor cells expressing mutant p53, induces au-
tophagy in cancer cells carrying both mutant and wild type p53.
Autophagy occurrence was detected by acridine orange staining,
anti-LC3 immunoﬂuorescent puncta and immunoblots, as well as by
EM observation of double-membraned AVs. Very interestingly, ultra-
structural analysis revealed signiﬁcant alteration of the ER. The ability
of PRIMA-1 to affect ER homeostasis has been previously suggested
on the basis of the observation that in Saos-2 cells carrying mutant
p53, PRIMA-1Met induced several genes associated with ER stress
[6]. However, our results represent the ﬁrst direct evidence that ER
is indeed a target of PRIMA-1 action. It is also noteworthy that ER
stress has been recognized as a putative regulator of the autophagic
signaling pathways, mainly but not exclusively through the activity
of BCL-2 family proteins [15,42], which supports the idea that a link
between PRIMA-1-induced ER stress and autophagy actually exists.
Mitochondrial damage can be also induced by PRIMA-1 as document-
ed by the presence of apparently well preserved or fragmented mito-
chondria in the AVs. This might originate from a massive induction of
signaling cascades that target mitochondria as demonstrated in can-
cer cells carrying exogenous mutant p53 treated with PRIMA-1Met [5].
The autophagy induced by PRIMA-1 appeared different from that
induced by serum starvation, a stimulus known to trigger a typical
autophagic process with a pro-survival function. Enhanced immunoﬂu-
orescence detection of LC3 puncta and the presence of numerous
AVs were a more frequent feature of PRIMA-1-treated cells than
serum-starved cells. Interestingly, abundant acridine orange-positive
AVOs as well as several RBs at ultrastructural level were identiﬁed
following PRIMA-1, but not after starvation. Such RBs containing
unrecognizable material or cell debris, are believed to be the remnants
of the auto-degradative activity occurring after fusion of lysosomes
with autophagocytic vacuoles, thus representing the late steps of the
autophagic process [31]. As such, they could probably be viewed as
the ultrastructural residues of AVOs detected in MDA-MB-231 cells,
which were likewise increased upon PRIMA-1 treatment. Morphologi-
cal evidence of the achievement of this ﬁnal step may be considered
the proof that in these cells treated with PRIMA-1, there is no block of
autophagy completion.
Autophagy was induced by PRIMA-1 also in T1 cells lacking mutant
p53, indicating that mutant p53 is not essential for the induction of
autophagy upon PRIMA-1 exposure. However, these cells appeared to
express a higher level of LC3 puncta already in the absence of treatment.
Upon 200 μMPRIMA-1 the autophagicmarkers increased, although to a
lower extent than in MDA-MB-231 cells. Indeed, the number of AVs
in 200 μM PRIMA-1 treated compared to untreated cells increased
13-fold inMDA-MB-231 and and 5-fold in T1 cells. Likewise, the volume
density of AVs increased up to 20-fold after PRIMA-1 in MDA-MB-231
but only up to 7-fold in T1 cells (Fig. 7). This suggests that the mutantp53 plays an inhibitory role on basal autophagy but its removal affects
the regulation of autophagy, weakening its induction by PRIMA-1.
These results are in keeping with the existence of a pro-survival func-
tion exerted by mutant p53 in these cells. As a matter of fact, compared
toMDA-MB-231, T1 cells deprived of this function aremore sensitive to
PRIMA-1, although they maintain the same sensitivity to another type
of molecule such as adriamycin [10].
The autophagic potential of PRIMA-1 has been detected also in
HCT116 cancer cells, regardless the presence of wild type p53,
again demonstrating that p53 is not essential for autophagy induc-
tion by this drug. However, in keeping with what has been already
reported [26], our results show that wild type p53 can inhibit basal
autophagy. Unlike what has been observed in T1, a signiﬁcantly
higher induction of autophagy was found in HCT116 p53−/− than
in HCT116 p53+/+ cells upon 50 μM PRIMA-1 (Fig. 7), as if the ab-
sence of wild type p53 lowered the threshold for autophagy induc-
tion by PRIMA-1. Noteworthy, HCT116 p53−/− cells were more
sensitive to the cytotoxic effect of PRIMA-1 than HCT116 p53+/+ cells
(Fig. 4), suggesting that in these cells a deregulated autophagy may lead
to cell death. It is to be noted that such a higher sensitivity of HCT116
p53−/− cells towards PRIMA-1 is not a peculiarity of this cell line per
se, since when other drugs, such as adriamycin or 5-ﬂuorouracil, were
used for survival experiments, HCT116 p53−/− cells appeared even
more viable than their p53+/+ counterpart (data not shown). Although
more experiments have to be performed on this issue, the greater sensi-
tivity of cells lacking p53 towards PRIMA-1 combinedwith a deregulated
autophagy may underline a role of autophagy in PRIMA-1 induced cell
death. The link between autophagy and cell death is still a matter of dis-
cussion [43,44]. It has been reported that low levels of basal autophagy
are pro-survival and help to maintain metabolic homeostasis. However,
in some cellular settings or when it occurs to a remarkable extent, au-
tophagy may contribute to or accompany cell death [42,45–47]. Interest-
ingly, the apoptotic and the autophagic response machineries share
common signals and a cross-talk between the two pathways indeed ex-
ists [19,45].
We have previously shown that in MDA-MB-231 cells treated with
PRIMA-1, mutant p53 translocated into nucleoli in a high percentage
of cells and this was associated to p53 degradation via ubiquitination,
and cell death [10]. To our opinion, this could indicate the triggering
of a protein degradation pathway that removes a pro-survival func-
tion of the mutant p53 [10]. Indeed, the degradation of mutant p53
induced by PRIMA-1 has been observed also in DLD1 cells (Supple-
mentary Fig. 3). On the other hand, in HCT116 and MCF7 cells, the
wild type p53 protein was induced (or stabilized) by treatment
with PRIMA-1 (Supplementary Fig. 3). These results indicate that
1911D. Russo et al. / Biochimica et Biophysica Acta 1833 (2013) 1904–1913the autophagy observed after PRIMA-1 exposure is not a direct conse-
quences of p53 induction, but again suggest a different role played by
mutant and wild type p53 in cancer cells undergoing autophagy.
In addition it should be mentioned that unfolded mutant p53 is pref-
erentially modiﬁed by PRIMA-1/APR-246 as compared to the cor-
rectly folded wild type protein [3] implying that a different effect of
PRIMA-1 directly on mutant or wild type p53 proteins is possible.
In conclusion, the data presented here showed for the ﬁrst time that
PRIMA-1 can trigger autophagy in cancer cells expressing both wild
type and mutant p53. Furthermore, although autophagy was induced
by PRIMA-1 regardless of the presence of p53, our results highlight a
modulating role of p53 on autophagy triggered by this molecule. In
particular, while wild type p53 may limit PRIMA-1 induced autophagy,
mutant p53, likely due to a gain of function activity of this protein, may
promote autophagy and sustain cell viability upon PRIMA-1. Since the
methylated form of PRIMA-1, namely APR-246, is presently employed
in phase I/II clinical trials for hematological malignancies and prostate
cancer and a ﬁrst-in-human study with this compound has been very
recently published [41], these results could be of interest for its thera-
peutic use in cancer treatment.
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